- Details
- In this Journal Club discussion, Rashid Sayyid and Zach Klaassen discuss the paper "Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review," published in Equity in Cancer Care. The study focuses on the prevalence of genetic testing among different racial groups in the US, and finds significant racial disparities in the use of germline genetic testing for prostate c...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a Journal of Nuclear Medicine publication titled, “The Prognostic Role of 68 Ga-PSMA11 PET-Based Response in Prostate Cancer Patients Undergoing Taxane-Based Chemotherapy.” This cutting-edge research explores the use of PSMA PET/CT imaging as an assessment tool in the biochemically recurrent setting, providing an alternative to conventional imaging methods....
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a publication by the MARCAP Group titled “Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer.” The study aims to validate intermediate clinical endpoints in advanced prostate cancer, which are faster to report, reducing resources required for clinical trials and potentially allowing quicker patient access to effective therapies. The...
|
- Details
- Rashid Sayyid and Zach Klaassen present the MAGNITUDE study that assessed the combination of niraparib and abiraterone acetate in treating mCRPC (metastatic castration-resistant prostate cancer) patients in the first-line setting. The study is notable due to the poor prognosis associated with mCRPC and the growing need for new treatments and combinations. Focusing on the homologous recombination r...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss an update of ENZAMET, a study published in Lancet Oncology, focused on metastatic hormone-sensitive prostate cancer (mHSPC). The study assesses the median overall survival of various patient subsets, emphasizing different median survivals for different groups and the efficacy of enzalutamide among 2,253 men, with 1,125 randomly assigned to treatment groups....
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the New England Journal of Medicine publication "Patient-Reported Outcomes 12 Years After Localized Prostate Cancer Treatment." The Prostate Testing for Cancer and Treatment (ProtecT) trial evaluated prostatectomy's functional and quality-of-life impacts, radiotherapy with neoadjuvant androgen deprivation, and active monitoring. Patients with low to intermed...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss The New England Journal of Medicine publication "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer." The ProtecT trial invited over 82,000 men between 50 and 69 years, and prostate cancer was diagnosed in 2,664 men, and of these men, just over 1,600 were randomized to either active monitoring, prostatectomy, or radiotherapy...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses "Inherited TP53 Variants and Risk of Prostate Cancer" comparing two cohorts: a Li-Fraumeni syndrome cohort of 163 men from 132 families and a prostate cancer cohort of 7,000 patients. This study aims to determine if gTP53 predisposes to prostate cancer, as there is no known association. Results showed that the incidence rate of prostate can...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication from the JCO Precision Oncology, "Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs." In this study, nearly one in five, or 17.2%, prostate cancer patients had positive germline mutations, including relativel...
|
- Details
- Zach Klaassen discusses an article entitled "Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study" in this UroToday Journal Club discussion. The UK Genetic Prostate Cancer Study investigated the association between family history and prostate cancer outcomes, including known prognostic factors, prostate cancer-specific mortality, and all-cause mortality....
|
